Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

FDA Approves New Atypical Antipsychotic, Caplyta

Posted by PeterMartin on December 23, 2019, at 21:54:26

December 23, 2019:

The exact mechanism of action of Caplyta in the treatment of schizophrenia is unknown, but it is believed to be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors.

The approval was based on results from 2 double-blind, placebo-controlled trials (Study 1 [N=335] and Study 2 [N=450]) that evaluated the efficacy of Caplyta in patients with schizophrenia for 28 days. Findings from Study 1 and Study 2 showed that Caplyta 42mg once daily demonstrated a statistically significant reduction from baseline to Day 28 in the Positive and Negative Syndrome Scale (PANSS) total score with a placebo-subtracted difference of -5.8 (95% CI: -10.5, -1.1) and -4.2 (95% CI: -7.8, -0.6), respectively.

From:
https://www.empr.com/home/news/fda-approves-new-atypical-antipsychotic-caplyta-to-treat-schizophrenia-in-adults/


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:PeterMartin thread:1107401
URL: http://www.dr-bob.org/babble/20191019/msgs/1107401.html